Login
$CGON
$84.48 -$0.30 (0.35%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Jim DeTore
Chief Financial Officer and Interim Principal Financial and Accounting Officer
61 Not stated $96,000
Arthur Kuan Also a director
President
35 Not stated $11,928,401
Vijay Kasturi
Chief Medical Officer
58 Since 2023
3 years
$3,599,947
Joshua F. Patterson
General Counsel, Chief Compliance Officer and Secretary
50 Since 2024
2 years
$2,364,380
Isabel Kalofonos
Chief Commercial Officer
Title from the Form 4 dated Oct 15, 2026
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
5.1 years
from year joined
CEO also chairs the board
Yes
Arthur Kuan
Director Age On board Independent Other public boards 2025 pay Source
Arthur Kuan
35 2017
9 years
Not stated Chunghwa Chemical Synthesis & Biotech (TPEX: 1762) Paid as CEO
Leonard Post
73 2018
8 years
Independent uniQure N.V. (Nasdaq: QURE) $500,127
Christina Rossi
50 2025
1 year
Independent Xilio Therapeutics, Inc. $575,150
Victor Tong, Jr.
42 2023
3 years
Independent Aardvark Therapeutics, Inc. $467,627
Susan Graf
53 2023
3 years
Independent Aardvark Therapeutics, Inc. $482,627
Brian Liu
37 2022
4 years
Independent None stated $475,127
James J. Mulé
73 2018
8 years
Independent None stated $457,627

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 24, 2026
holders of more than 5% of our capital stock and entities with which certain of our directors are affiliated
holders of more than 5% of our capital stock listed above as well as entities with which certain of our directors are affiliated
Amount not stated

Investors' Rights Agreement providing registration rights and certain covenants; all rights except registration rights terminated upon the IPO closing on December 16, 2024.

With holders of our redeemable convertible preferred stock and certain holders of our common stock Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support